|
![]() |
|
PAGE: 1 2 3 4 5 6 7 8 9 10 11 | Next - Last Anti-Migraine Therapies 2005 B2B Conferences Attend the visiongain's b2b conference, ANTI-MIGRAINE THERAPIES 2005: IMPROVING DISEASE UNDERSTANDING, DRUG DELIVERY AND FUTURE TARGETS. This conference's objective is to provide a unique forum to discuss the new developments in significant areas of the anti-migraine therapies market. This includes new research data to innovations in drug delivery to future targets for drugs. - visiongain, December 03, 2004 visiongain predicts by 2009 Orphan drugs will grow to be worth almost $65 billionAccording to the latest visiongain report "Orphan Drugs: Future Directions for a High Growth Market 2004-2009", in 1983 there were just 10 orphan drugs available to treat rare diseases. However in the space of 20 years there are now 210 different drugs resulting in a market that is worth more than $27 billion today. The high cost of orphan drugs and lack of competition in the market means that the industry is extremely profitable for many drugs. - visiongain, December 03, 2004 Blockbuster drugs expected to rise by 93% to $262 billion by 2009 predicts visiongainAccording to the latest visiongain report "Blockbuster Drugs: A Current Assessment and Outlook for Creating Future Blockbusters", A blockbuster drug is defined as a medicine that generates more than $1 billion (U.S.) in sales in a year. According to the latest visiongain report " The Cardiovascular Report - 3rd Annual Edition", Cardiovascular is the leading therapeutic category in the pharmaceutical industry worldwide and with new drugs in the pipeline, competition in the cardiovascular market has never been greater. - visiongain, November 01, 2004 "$19.6 billion spent on drug discovery and set to increase by 6%" reports visiongainWith increasing lead times and cost of drug development, companies need to find new drugs, quicker and cheaper than before. At least 50 of the 433 are "me-too" drugs, and all are based on eight chemical scaffolds. This presents how hard it is to find or make a new molecule that has an important therapeutic effect. What has become obvious is that it takes longer, costs more and is much harder to discover new drugs than it used to be. - visiongain, October 27, 2004 HIPAACOACH - An online HIPAA Security Course that saves employers time and moneyThe HIPAAcoach HIPAA Security Basics course offers employers an easy, inexpensive way to provide basic security awareness and training to their workforce. - Internet Portfolio Group, September 10, 2004 PAGE: 1 2 3 4 5 6 7 8 9 10 11 | Next - Last |
| Copyright © 2004 - 2008 PR9.NET - All rights reserved | RSS Feeds | Submit Press Release | Terms of Service | Privacy Policy |